Cardiovascular disease is the most important complication and the main reason for the mortality in hemodialysis (HD) patients. L-type dihydropyridine calcium channel blockers (L-TCCs) are frequently used to control blood pressure in HD patients. The main cause of anemia in HD patients is erythropoietin (EPO) and iron deficiency. It was demonstrated that, L-TCCs impeded the calcium influx and blocked the effect of EPO in vitro. In addition, in recent years, it has been shown a significant effect of L-TCCs on the increase in cellular iron uptake. We hypothesized that the use of amlodipine in HD patients could inhibit the activity of EPO and lead to the need for increasing doses of erythropoiesis stimulating agents (ESA). The purpose of our work was to investigate whether amlodipine use was associated with increasing dose of intravenous iron and ESA. METHODS: It was a regional multicenter retrospective observational study. A total of 88 adult HD patients were classified into 2 groups based on amlodipine usage: the 1st group (n ¼ 27) received amlodipine for at least 6 months and the 2nd one (n ¼ 61) received no any treatment of amlodipine. The patients of the both groups did not differ by such parameters as sex difference (v2 ¼ 0.14; p ¼ 0.71), age (p ¼ 0.35), duration of HD treatment (p ¼ 0.23) and comorbidity index (p ¼ 0.59). The hemoglobin level (Hb), the dose of intravenous iron and continuous erythropoietin receptor activator (CERA) were analyzed. Statistical analysis included Student's t-test, nonparametric (U-) Mann-Whitney's test and Fisher's exact test. Relative risk (RR) and odds ratio (OR) were calculated using logistic regression. RESULTS: A total, intravenous iron was used in 43/88 (49 %) HD patients, CERA was prescribed to 68/88 (77 %) patients. The prescribing of intravenous iron was in 22/27 (81.5%) patients of the amlodipine group and in 21/61 (34.4%) patients of the 2nd group (v2 ¼ 16.4; h ¼ 0.0001). CERA was administered to 25/27 (92.6%) patients in the 1st group and 43/61 (70.5%) patients in non-user group (v2 ¼ 5.2; h ¼ 0.02). The Hb level in the patients of Group I tended to decrease, but, it did not differ statistically from the patients of Group II: 106.5 [100.1-110] g / l vs 111 [107][108][109][110][111][112][113] 
SP358 THE COST-EFFECTIVENESS OF CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR ONCE MONTHLY VERSUS EPOETIN THRICE WEEKLY FOR ANAEMIA MANAGEMENT IN CHRONIC HAEMODIALYSIS PATIENTS

INTRODUCTION AND AIMS:
The purpose of this study was to carry out a cost-effectiveness analysis (CEA) to evaluate the impact of switching patients from their current short-acting ESA therapy to CERA once monthly in a real-world setting, to maintain haemoglobin (Hb) within the range 10.5-12 g/dL. METHODS: In a multicenter prospective cohort study and cost-effectiveness analysis, chronic haemodialysis patients (CHP), being treated with EpoB, were selected for two periods of follow-up: period 1, maintaining prior treatment with EpoB, and period 2, conversion to CERA once monthly. Hb concentrations and costs were measured monthly. The cost-effectiveness analysis was conducted from the healthcare payer perspective, and we applied decision analytic techniques to evaluate the average and incremental cost-effectiveness of EpoB and CERA in the treatment of anaemia. Key model inputs included clinically relevant effectiveness measures, which was measured by the clinical success rate of treatment (CSR), defined as the proportion of patients successfully achieving the Hb target as well as drug acquisition costs for both treatments considered. Model outputs were expected cost-effectiveness ratio and the incremental costeffectiveness ratio (ICER) that represents the additional cost and effectiveness obtained, when CERA regime is compared to the EpoB regime.In this order, we considered the effectiveness and cost in terms of Hb level achieved during the two periods of six months of follow-up. Two Hb ranges were considered: 10,5 to 12 g/dL (the recommended range), higher than 12 g/dL or lower than 10,5 g/dL. Measurements of Hb were performed every 4 weeks during the study period; the mean of six consecutive measures at each phase of the study was used to categorize patients on the two groups considering Hb ranges. In our analysis, the CSR was calculated at two time periods: (1) from month À6 to month 0 for EpoB and (2) from month 0 to month 6 for CERA. Costs were calculated for each patient in the 2 periods of the study, based on 24-week drug acquisition costs, and these patient-specific costs were averaged across patients within the same range of Hb. RESULTS: 75 CHP completed the study, with a mean age of 52.9 6 14.3 years. Baseline Hb was 11.14 6 1.18 g/dL in EpoB phase and 11.46 6 0.79 g/dL in CERA phase; we observed a significant increase in the proportion of patients successfully treated (Hb within the recommended range), 65.3% versus 70.7%, p: 0.008, and in the average effectiveness by 4% (0.55 versus 0.59).Based on 6-month drug acquisition cost, the mean per patient cost was 1644.2 6 859.4$ for EpoB and 1515.5 6 713$ for CERA, projected annual per patient costs were 3288.49 6 1718.9$ and 3030.19 6 1426$, respectively, with a cost saving associated with CERA at À258.3$. Average annual effectiveness estimated by the model was 0.55 for EpoB and 0.59 for CERA, and average cost-effectiveness ratios were 6013.86$ and 5173.64$, with an ICER CERA to EpoB at À6457.5$. CONCLUSIONS: Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB.
SP359 DOES FIBROBLAST GROWTH FACTOR FGF23 PLAY A ROLE IN ANEMIA OF DIABETIC PATIENTS ON REGULAR HEMODIALYSIS?
Adel Afifi INTRODUCTION AND AIMS: fibroblast growth factor FGF-23 is believed to contribute to the development of anemia in dialysis patients. Diabetes mellitus is associated with higher rates of cardiovascular disease and fractures despite high bone mineral density, so the evaluation of FGF23 and its relationship with diabetes mellitus is of interest. The aim of this work was to study the relationship between fibroblast growth factor-23 and anemia in diabetic patients on regular hemodialysis. METHODS: 45 diabetic patients with ESKD on regular HD and the level of hemoglobin less than 11gm/dl (Group 1) and 45 patients non diabetic, ESKD on regular HD and the level of hemoglobin less than 11gm/dl (Group 2) were included in the study. For each patient the following was done:Pre dialysis serum calcium, serum phosphorus, hemoglobin level, serum PTH, serum iron, total iron binding capacity, ferritin, serum albumin and serum FGF23. RESULTS: Serum FGF-23 was significantly higher in diabetic than non-diabetic patients. PTH level was significantly higher in the non diabetic group. There is no statistically significant difference between the studied groups as regard the anaemic parameters, serum Calcium nor serum phosphorus. FGF23 had an inverse correlation to Hb level (P <0.001) & serum albumin (P ¼ 0.01). FGF23 had a positive correlation to PTH in all the studied groups (P ¼ 0.01).In all studied patients, there was no correlation between FGF-23, iron profile and serum phosphorus. CONCLUSIONS: Serum FGF-23 is significantly higher in diabetic patients than nondiabetics. Serum FGF-23 level in hemodialysis patients has a negative correlation with anemia in both groups. 
